Literature DB >> 12134965

Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders.

Takeshi Shiiki1, Yukiya Hashimoto, Ken-ichi Inui.   

Abstract

Mesh：

Year:  2002        PMID： 12134965     DOI： 10.1023/a:1016181505556

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  14 in total

1.  Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II.

Authors:  J A Miller; K Thai; J W Scholey
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

2.  10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.

Authors:  P Dalén; M L Dahl; M L Bernal Ruiz; J Nordin; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1998-04       Impact factor: 6.875

3.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

4.  Serotonin transporter gene polymorphism and antidepressant response.

Authors:  D K Kim; S W Lim; S Lee; S E Sohn; S Kim; C G Hahn; B J Carroll
Journal:  Neuroreport       Date:  2000-01-17       Impact factor: 1.837

5.  CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour.

Authors:  S T Saarikoski; F Sata; K Husgafvel-Pursiainen; M Rautalahti; J Haukka; O Impivaara; J Järvisalo; H Vainio; A Hirvonen
Journal:  Pharmacogenetics       Date:  2000-02

6.  VDR genotype and response to etidronate therapy in late postmenopausal women.

Authors:  J Marc; J Prezelj; R Komel; A Kocijancic
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

7.  A simulation study comparing designs for dose ranging.

Authors:  L B Sheiner; Y Hashimoto; S L Beal
Journal:  Stat Med       Date:  1991-03       Impact factor: 2.373

8.  Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.

Authors:  A Odani; Y Hashimoto; Y Otsuki; Y Uwai; H Hattori; K Furusho; K Inui
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

9.  Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

Authors:  M Masellis; V Basile; H Y Meltzer; J A Lieberman; S Sevy; F M Macciardi; P Cola; A Howard; F Badri; M M Nöthen; W Kalow; J L Kennedy
Journal:  Neuropsychopharmacology       Date:  1998-08       Impact factor: 7.853

10.  Study designs for dose-ranging.

Authors:  L B Sheiner; S L Beal; N C Sambol
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875
View more
  2 in total

1.  Evaluation of mixture modeling with count data using NONMEM.

Authors:  Bill Frame; Raymond Miller; Richard L Lalonde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-06       Impact factor: 2.745

2.  Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.

Authors:  Céline Dartois; Gilles Freyer; Mauricette Michallet; Emilie Hénin; Benoît You; Isabelle Darlavoix; Claudine Vermot-Desroches; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.